Chk2*1100delC Acts in synergy with the Ron receptor tyrosine kinase to accelerate mammary tumorigenesis in mice

Cancer Lett. 2010 Oct 28;296(2):186-93. doi: 10.1016/j.canlet.2010.04.011.

Abstract

The CHEK2 (Chk2 in mice) polymorphic variant, CHEK2*1100delC, leads to genomic instability and is associated with an increased risk for breast cancer. The Ron receptor tyrosine kinase is overexpressed in a large fraction of human breast cancers. Here, we asked whether the low penetrance Chk2*1100delC allele alters the tumorigenic efficacy of Ron in the development of mammary tumors in a mouse model. Our data demonstrate that Ron overexpression on a Chk2*1100delC background accelerates the development of mammary tumors, and shows that pathways mediated by a tyrosine kinase receptor and a regulator of the cell cycle can act to hasten tumorigenesis in vivo.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Breast Neoplasms / epidemiology
  • Breast Neoplasms / genetics*
  • Breast Neoplasms / pathology
  • Cell Cycle
  • Cell Division
  • Cell Line, Tumor
  • Checkpoint Kinase 2
  • Female
  • Genetic Variation
  • Humans
  • Immunohistochemistry
  • Mammary Neoplasms, Animal / genetics*
  • Mammary Neoplasms, Animal / pathology
  • Mice
  • Polymorphism, Genetic
  • Protein Serine-Threonine Kinases / genetics*
  • Receptor Protein-Tyrosine Kinases / genetics*
  • Risk Factors
  • Sequence Deletion

Substances

  • Checkpoint Kinase 2
  • RON protein
  • Receptor Protein-Tyrosine Kinases
  • CHEK2 protein, human
  • Chek2 protein, mouse
  • Protein Serine-Threonine Kinases